Natural Product (NP) Details
| General Information of the NP (ID: NP6954) | |||||
|---|---|---|---|---|---|
| Name |
Artesunate
|
||||
| Synonyms |
Artesunate; Artesunic acid; Arsumax; Dihydroqinghasu hemsuccinate; 88495-63-0; Arinate; Artesunatum; Artesunato; Plasmotrin; Qinghaozhi; Saphnate; Asumax; Gsunate Forte; Plasmotrim; UNII-60W3249T9M; CHEBI:63918; Succinyl dihydroartemisinin; 60W3249T9M; Arsuamoon; Butanedioic acid, 1-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl] ester; cosunate; Artesunata; SM 804; Cosinate; Zysunate; 4-Oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl)oxy)butanoic acid; 4-oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl)oxy)butanoic acid; 4-oxo-4-{[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-yl]oxy}butanoic acid; Armax 200; Artesunatum [INN-Latin]; Artesunato [INN-Spanish]; Artsuna; Nuartez; Artesunate [USAN:INN:BAN]; HSDB 7458; NSC-712571; Quinghaosu reduced succinate ester; D95; Dihydroartemisinine-12alpha-succinate; WR 256283; WR-256283; MLS006011590; CHEMBL361497; GTPL9956; SCHEMBL14552891; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, hydrogen succinate; ACT02643; HY-N0193; STR09744; BDBM50248021; ZINC14096305; CS-8151; DB09274; NCGC00164600-10; SMR002499399; Q707939; BRD-K54634444-001-05-9; WR-256283;ART;Armax 200;SM-804;HSDB-7458; 4-Oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10-yl hydrogen butanedioate; 4-oxo-4-{[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0?,(1)(3).0?,(1)(3)]hexadecan-10-yl]oxy}butanoic acid; Butanedioic acid, mono((3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester
Click to Show/Hide
|
||||
| Species Origin | Artemisia annua ... | Click to Show/Hide | |||
| Artemisia annua | |||||
| Disease | Malaria [ICD-11: 1F40] | Approved | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C19H28O8
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)OC(=O)CCC(=O)O)C
|
||||
| InChI |
1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1
|
||||
| InChIKey |
FIHJKUPKCHIPAT-AHIGJZGOSA-N
|
||||
| CAS Number |
CAS 88495-63-0
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP7 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | GTF2H3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | p38 beta | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| In-vivo Model | For a xenograft model, 1.0 * 107/mL A549 cell was injected into the right flanks of the five-week-old female nude mice (nu/nu) with weight of 13-16 g. | |||||
| Experimental
Result(s) |
ART exhibited significant anti-tumor effect on A549 cells and this efficiency could be enhanced by combination with CIS. | |||||
| Tetramethylpyrazine | Dissociative neurological symptom disorder | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BDNF | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | GFAP | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ICAM1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | NGF | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | NTF3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VCAM1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | For a xenograft model, 1 * 106 parasitized red blood cells (pRBCs) were injectedinto C57BL/6 mice via intraperitoneal (i.p.). | |||||
| Experimental
Result(s) |
The neuroprotective effects of artesunate + tetramethylpyrazine were mainly related to proteins involved in axon development and transportation between blood and brain. | |||||
| Sorafenib | Renal cell carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | c-RAF | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SK-HEP-1 | CVCL_0525 | Hepatocellular carcinoma | Homo sapiens | ||
| SMMC-7721 | CVCL_0534 | Hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | For a xenograft model, 1 * 107 SK-hep1 cells were injected subcutaneously into 4-6 weeks old BALB/c nu/nu mice. | |||||
| Experimental
Result(s) |
Sor and Art combination promotes a dual inhibitory effect on both RAF/MAPK and PI3K/AKT/mTOR pathways which contributes to apoptosis burst. | |||||
| Tafenoquine | Malaria | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Biological
Regulation |
Increase | Rapid clearance of B. microti | ||||
| In-vitro Model | Babesia bovis | Microorganism model | Babesia bovis | |||
| In-vivo Model | 8-9-weeks-old BALB/c female mice were used in this study. | |||||
| Experimental
Result(s) |
Tafenoquine (10 mg/kg, base), combined or not with artesunate, but not mefloquine, induced rapid clearance of B. microti in vivo by microscopy, but mice remained PCR-positive. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) | Molecule Info | [1] | |
